FOS Immunohistochemical Staining of Colorectal Cancer and Its Adjacent Tissues

NCT ID: NCT05698082

Last Updated: 2023-01-26

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-12-01

Study Completion Date

2025-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Colorectal cancer tissue sections were obtained according to the inclusion criteria. The formalin was used to immersed all cancer specimens. And tissues were cut to 5 μm thickness and placed on glass slides before staining. Endogenous peroxidase activity was inhibited and blocked by de-paraffinizing, rehydrating, and using 5% bovine serum albumin at 37ºC for 30 min. The treated sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Cancer Monkey Pox

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test group-stained by FOS antibody

Sixty colorectal cancer tissue sections were included. The tissue was cut to 5 μm thick and placed on a glass slide for staining. Endogenous peroxidase activity was inhibited and blocked by deparaffin, rehydration, and treatment with 5% bovine serum albumin for 30 min at 37 ° C. The treated sections were incubated with anti-FOS (promab 30360) overnight at 4 ° C and washed three times with PBS. After that, it was required to incubate with secondary anti-peroxidation sunflower for 30 min at 37 ° C. After washing three times with PBS, the images were developed in diamine benzidine and micrographs were obtained under a light microscope.

Group Type EXPERIMENTAL

Immunohistochemical staining with anti-FOS

Intervention Type DIAGNOSTIC_TEST

The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Immunohistochemical staining with anti-FOS

The tissue sections were incubated with anti-FOS (promab 30360) at 4ºC overnight and washed three times with PBS. After that, it is required that incubation with secondary anti-peroxidation sunflower at 37ºC for 30 minutes. After washing three times again with PBS, the sections were developed in diaminobenzidine and microscopic images were made by light microscopy.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (a) patients with histologically confirmed CRC (b) patients who underwent resection of the primary tumor (c) patients at first visit who had not received treatment before blood testing.

Exclusion Criteria

* (a) familial adenomatous polyposis or hereditary colon cancer (b) no signs of clinical infection, such as fever, on the day of blood collection; And (c) patients with multiple primary tumors during hospitalization.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

xiaoliang Huang

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

xiaoliang Huang

clinical Professor

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Guangxi Medical University Cancer Hospital

Nanning, Guangxi, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Xiaoliang Huang, Dr.

Role: CONTACT

0086-13617713823

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Xiangliang Huang, Dr.

Role: primary

+8613617713823

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KY-2020-305

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.